ESR1 and cancer: Exposure to endocrine-active compounds like BPA could also subvert the effects of endocrine therapies like Tamoxifen, which reduce the risk of cancer recurrence, thereby promoting the growth and spread of estrogen receptor-positive tumors [113,114].